FDA Approves Stand-alone 3D Screening With Siemens Tomosynthesis Platform

Siemens Healthineers has announced that the Food and Drug Administration (FDA) has approved the use of 3D-only screening mammography utilizing the company’s Mammomat Inspiration with Tomosynthesis Option digital mammography system. The Siemens system is the first and only 3D digital breast tomosynthesis (DBT) platform to be approved by the FDA … Continue reading

Share

Siemens enters field of molecular services for oncology

Siemens Healthineers has expanded its diagnostics portfolio with the acquisition of NEO New Oncology AG, Cologne, Germany. The company’s cancer genome diagnostic platform NEO(1) will support pathologists and oncologists with comprehensive molecular information to help select targeted cancer therapies. NEO New Oncology is developing molecular profiling assays based on NGS … Continue reading

Share